Maladies peptiques [Progress in 2008 for acid related diseases]


Autoria(s): Jornod P.; Vouillamoz D.; Viani F.; Nichita C.; Dorta G.
Data(s)

2009

Resumo

The treatment of reflux disease did not change in the review period. PPI therapy remains the first line treatment and surgery the second line approach. Endoscopic anti-reflux procedures should be only performed in controlled studies. Beside the classic triple therapy, sequential treatment of Helicobacter pylori infection can today be considered as a first line therapy. PPI are effective in the prevention of gastroduodenal lesions and in the treatment of dyspeptic symptoms induced by NSAIDs treatment. Only patients younger then 65 years and without any risk factors do not need a preventive PPI prescription during classic NSAIDS treatment.

Identificador

http://serval.unil.ch/?id=serval:BIB_46E5D698B7F2

isbn:1660-9379

pmid:19271427

Idioma(s)

fr

Fonte

Revue Médicale Suisse, vol. 5, no. 187, pp. 167-175

Palavras-Chave #Anti-Ulcer Agents; Digestive System Surgical Procedures; Gastroesophageal Reflux; Helicobacter Infections; Humans; Proton Pump Inhibitors
Tipo

info:eu-repo/semantics/article

article